Dr. Reddy's UK API Facility USFDA Inspection Closed VAI

Date: August 14, 2026

Regulatory Update

Dr. Reddy's Laboratories Limited has provided an update regarding a Good Manufacturing Practice (GMP) inspection conducted by the United States Food & Drug Administration (USFDA).

The inspection was conducted at the company's Active Pharmaceutical Ingredient (API) manufacturing facility located in Mirfield, West Yorkshire, United Kingdom.

The USFDA has classified the outcome of this inspection as 'Voluntary Action Indicated (VAI)'.

The regulatory agency has concluded that the inspection is officially closed under the provision 21 CFR 20.64(d)(3).

This disclosure serves as a follow-up to the company's initial intimation regarding the inspection, which was made to the exchanges on September 8, 2025.